Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.71
-0.0400-2.29%
Post-market: 1.710.00000.00%19:59 EDT
Volume:48.41K
Turnover:83.99K
Market Cap:3.14M
PE:-0.06
High:1.82
Open:1.77
Low:1.71
Close:1.75
52wk High:29.28
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.02
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.42
PE(LYR):-0.03

Loading ...

HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement

Reuters
·
Aug 15

Top Brass Makes Bold Move on HCW Biologics Shares

TIPRANKS
·
Aug 01

HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56

Reuters
·
Aug 01

HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement

Reuters
·
Jul 29

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

THOMSON REUTERS
·
Jul 29

HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program

Reuters
·
Jul 23

HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

GlobeNewswire
·
Jul 23

HCW Biologics Resolves Disputes, Clears Miramar Property Liens

TIPRANKS
·
Jul 01

HCW Biologics - Pays in Full Amounts Owed to Eirgenix Under Settlement Agreement on May 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - to Report Settlement of $2.8 Mln Disputed Accounts Payable in Q2 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - B&I Contractors Files Voluntary Dismissal with Prejudice Against HCW Biologics on June 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics Says B&I Contractors Drops Florida Lien Crossclaims, Settles Dispute over USD 1.1 Million Lien

Reuters
·
Jul 01

HCW Biologics regains compliance with Nasdaq

TIPRANKS
·
Jun 30

HCW Biologics Executes 1-for-6 Reverse Stock Split

Reuters
·
Jun 30

HCW Biologics Regained Compliance with Bid Price Rule Per NASDAQ Compliance Letter

THOMSON REUTERS
·
Jun 30

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

GlobeNewswire
·
Jun 30